Similarly, in one study of healthy volunteers, a transient increase in heart rate was observed with a therapeutic dose of lixisenatide (20 μg), but no mean increases in heart rate were observed with this GLP-1 receptor agonist in phase 3, placebo-controlled studies of individuals with T2D [25]. Here, GLP1R is linked to type 2 diabetes mellitus.